XPF-002

DRUG2 trials

Sponsors

Xenon Pharmaceuticals Inc.

Conditions

Inherited ErythromelalgiaPostherpetic NeuralgiaPrimary Erythromelalgia

Phase 1

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

CompletedNCT01486446

Xenon Pharmaceuticals Inc.Inherited Erythromelalgia, Primary Erythromelalgia

Start: 2011-12-31End: 2012-05-31Updated: 2014-04-14

Phase 2

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

CompletedNCT01195636

Xenon Pharmaceuticals Inc.Postherpetic Neuralgia

Start: 2010-08-31End: 2011-03-31Updated: 2013-11-25